MX2023012521A - Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. - Google Patents
Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.Info
- Publication number
- MX2023012521A MX2023012521A MX2023012521A MX2023012521A MX2023012521A MX 2023012521 A MX2023012521 A MX 2023012521A MX 2023012521 A MX2023012521 A MX 2023012521A MX 2023012521 A MX2023012521 A MX 2023012521A MX 2023012521 A MX2023012521 A MX 2023012521A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- hydroxypropan
- pyrrolidine
- methylphenyl
- salts
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- GZMYLSJUNSCMTD-MOPGFXCFSA-N OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 Chemical compound OC[C@@H](C)NC1=NC(=CC(=C1)C=1C=C(C=CC=1C)NC(=O)N1C[C@@H](CC1)CC(F)(F)F)N1CCOCC1 GZMYLSJUNSCMTD-MOPGFXCFSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178752P | 2021-04-23 | 2021-04-23 | |
| PCT/US2022/025815 WO2022226221A1 (en) | 2021-04-23 | 2022-04-21 | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012521A true MX2023012521A (es) | 2023-12-15 |
Family
ID=83723159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012521A MX2023012521A (es) | 2021-04-23 | 2022-04-21 | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240208931A1 (https=) |
| EP (1) | EP4326255A4 (https=) |
| JP (1) | JP7825636B2 (https=) |
| KR (1) | KR20240000540A (https=) |
| CN (1) | CN117529313A (https=) |
| AU (1) | AU2022261159A1 (https=) |
| BR (1) | BR112023021916A2 (https=) |
| CA (1) | CA3216258A1 (https=) |
| IL (1) | IL307910A (https=) |
| MX (1) | MX2023012521A (https=) |
| WO (1) | WO2022226221A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| BR112023021913A2 (pt) | 2021-04-23 | 2024-01-16 | Kinnate Biopharma Inc | Tratamento de câncer com inibidor de raf |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR20210055042A (ko) * | 2018-07-31 | 2021-05-14 | 오스칸 그룹 홀딩스 엘티디 | “고체의 자가-유화 약학 조성물” |
| WO2020198058A1 (en) * | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| TW202106684A (zh) * | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| JP7626910B2 (ja) * | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Ｒａｆキナーゼの阻害剤 |
-
2022
- 2022-04-21 EP EP22792520.3A patent/EP4326255A4/en active Pending
- 2022-04-21 IL IL307910A patent/IL307910A/en unknown
- 2022-04-21 US US18/556,243 patent/US20240208931A1/en active Pending
- 2022-04-21 JP JP2023565206A patent/JP7825636B2/ja active Active
- 2022-04-21 CN CN202280044060.6A patent/CN117529313A/zh active Pending
- 2022-04-21 MX MX2023012521A patent/MX2023012521A/es unknown
- 2022-04-21 BR BR112023021916A patent/BR112023021916A2/pt unknown
- 2022-04-21 KR KR1020237039724A patent/KR20240000540A/ko active Pending
- 2022-04-21 WO PCT/US2022/025815 patent/WO2022226221A1/en not_active Ceased
- 2022-04-21 CA CA3216258A patent/CA3216258A1/en active Pending
- 2022-04-21 AU AU2022261159A patent/AU2022261159A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240000540A (ko) | 2024-01-02 |
| IL307910A (en) | 2023-12-01 |
| AU2022261159A1 (en) | 2023-11-23 |
| JP2024517431A (ja) | 2024-04-22 |
| CN117529313A (zh) | 2024-02-06 |
| US20240208931A1 (en) | 2024-06-27 |
| BR112023021916A2 (pt) | 2023-12-19 |
| JP7825636B2 (ja) | 2026-03-06 |
| EP4326255A4 (en) | 2025-03-12 |
| CA3216258A1 (en) | 2022-10-27 |
| TW202309018A (zh) | 2023-03-01 |
| WO2022226221A1 (en) | 2022-10-27 |
| EP4326255A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| GEP20115302B (en) | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | |
| JP2019059760A5 (https=) | ||
| EP4616913A3 (en) | Gcn2 inhibitors and uses thereof | |
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| EA200400476A1 (ru) | Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
| UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
| MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| JP2018090566A5 (https=) | ||
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| ATE339205T1 (de) | (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen | |
| NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| MX2023007287A (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas. | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| JOP20200133A1 (ar) | طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً | |
| WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| CR20230118A (es) | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |